847062-98-0Relevant articles and documents
RuPHOX-Ru-Catalyzed Selective Asymmetric Hydrogenation of Exocyclic α,β-Unsaturated Pentanones
Li, Jing,Liu, Delong,Liu, Yangang,Lu, Yufei,Wang, Yanzhao,Zhang, Wanbin,Zhu, Yue
supporting information, (2019/08/26)
A RuPHOX-Ru catalyzed selective asymmetric hydrogenation of exocyclic α,β-unsaturated ketones has been developed, furnishing the corresponding chiral exocyclic allylic alcohols in high yields and with up to >99.5percent ee. The reaction could be performed on a gram scale with a relatively low catalyst loading (up to 10000 S/C) without any loss in reaction activity and enantioselectivity. The resulting hydrogenated products could be easily transformed to several biologically active compounds with high asymmetric performance. The asymmetric protocol provides an efficient methodology for the synthesis of chiral exocyclic allylic alcohols.
Ultrasound mediation for efficient synthesis of monoarylidene derivatives of homo- and heterocyclic ketones
Mojtahedi, Mohammad M.,Abaee, M. Saeed,Samianifard, Mehdieh,Shamloo, Akram,Padyab, Masoomeh,Mesbah, A. Wahid,Harms, Klaus
, p. 924 - 930 (2013/03/13)
Ultrasonic irradiation was efficiently used for high yield synthesis of monoarylidene derivatives of cyclic systems directly from the reaction of ketone with various aldehydes under solvent-free conditions. Reactions took place rapidly in the presence of catalytic amounts of pyrrolidine, while no significant formation of the undesired bis by-products was observed. Moreover, the procedure was applicable to both homo- and heterocyclic ketones.
2-METHYLENE-5-SUBSTITUTED-METHYLENECYCLOPENTANONE DERIVATIVES AND USE THEREOF
-
Page/Page column 11, (2011/04/18)
The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately.
